Showing 1441-1450 of 1685 results for "".
- J&J Vision Announces Collaboration with Menicon to Bring Forward Contact Lenses for Childrenhttps://modernod.com/news/jj-vision-announces-collaboration-with-menicon-to-bring-forward-contact-lenses-for-children/2479057/Johnson & Johnson Vision announced a global strategic collaboration with Menicon, a manufacturer of contact lenses. As part of the collaboration, Menicon will develop and manufacture the contact lenses to help manage the progression of myopia in children. Johnson & Johnson Vision will foc
- J&J’s Coronavirus Vaccine Garners WHO Emergency-Use Listinghttps://modernod.com/news/jjs-coronavirus-vaccine-garners-who-emergency-use-listing/2478968/Johnson & Johnson said that the World Health Organization (WHO) has issued an emergency-use listing for its single-dose coronavirus vaccine Ad26.COV2.S to prevent COVID-19 in people 18 years and older. Chief scientific officer Paul Stoffels stated that “achieving this important prerequi
- J&J’s COVID-19 Vaccine Wins FDA Authorization for Emergency Usehttps://modernod.com/news/jjs-covid-19-vaccine-wins-fda-authorization-for-emergency-use/2478921/The US has added a third option to its arsenal of COVID-19 vaccines after the FDA authorized Johnson & Johnson’s single-dose candidate Ad26.COV2.S for emergency use in people 18 years and older on Saturday. Peter Marks, director of the FDA’s Center for Biologics Evaluation a
- One-Dose J&J COVID-19 Vaccine Meets Criteria as Safe and Effective, FDA Report Findshttps://modernod.com/news/one-dose-jj-covid-19-vaccine-meets-criteria-as-safe-and-effective-fda-report-finds/2478912/Detailed information on a Johnson & Johnson candidate vaccine for COVID-19 raises no safety concerns, according to a report released early Wednesday, according to a USA Today
- J&J Submits Single-Dose COVID-19 Vaccine for EMA Reviewhttps://modernod.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/The European Medicines Agency announced Tuesday that it has received a conditional marketing application for Johnson & Johnson’s COVID-19 vaccine candidate Ad26.COV2.S, and that it intends to review the submission under an accelerated timetable. The regulator indicated that the fi
- J&J Files Single-Dose COVID-19 Vaccine for US Emergency Usehttps://modernod.com/news/jj-files-single-dose-covid-19-vaccine-for-us-emergency-use/2478836/Johnson & Johnson submitted a request to the FDA seeking an emergency-use authorization (EUA) for its COVID-19 vaccine candidate Ad26.COV2.S. Paul Stoffels, the company’s chief scientific officer, called the filing “a pivotal step toward reducing the burden of disease for people g
- J&J’s Single-Dose COVID-19 Vaccine 66% Effectivehttps://modernod.com/news/jjs-single-dose-covid-19-vaccine-66-effective/2478814/Johnson & Johnson reported topline results Friday showing that its investigational single-dose vaccine candidate Ad26.COV2.S met all primary and key secondary endpoints of the phase 3 ENSEMBLE study, with an overall efficacy rate of 66% at preventing moderate-to-severe COVID-19, 28 days after
- AstraZeneca, J&J Say Their COVID-19 Vaccine Trials Back on Track in UShttps://modernod.com/news/astrazeneca-jj-say-their-covid-19-vaccine-trials-back-on-track-in-us/2478455/AstraZeneca announced Friday that it has been cleared to restart its phase 3 COVID-19 vaccine trial in the US. The company, which is co-developing AZD1222 with the University of Oxford, had paused global testing of the vaccine candidate early last month after a UK participant fell ill with what i
- J&J Pauses COVID-19 Vaccine Studies After “Unexplained Illness”https://modernod.com/news/jj-pauses-covid-19-vaccine-studies-after-unexplained-illness/2478407/Johnson & Johnson confirmed that it paused further dosing in all clinical studies of its COVID-19 vaccine candidate JNJ-78436735, including the phase 3 ENSEMBLE trial, due to an “unexplained illness” in a participant. The company noted that the subject’s illness is being rev
- J&J’s COVID-19 Vaccine “Highly Immunogenic” in Early-Stage Testinghttps://modernod.com/news/jjs-covid-19-vaccine-highly-immunogenic-in-early-stage-testing/2478332/Interim phase 1/2a study results for Johnson & Johnson’s experimental COVID-19 vaccine JNJ-78436735 have been published online on the preprint server medRxiv, with researchers saying that a single dose was “well tolerated and highly immunogenic,” and that the findings warran